Femalegra: The Clinically-Validated Treatment for Female Sexual Arousal Disorder
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.02 | $50.20 (0%) | 🛒 Add to cart |
| 20 | $3.01 | $100.41 $60.24 (40%) | 🛒 Add to cart |
| 30 | $2.34 | $150.61 $70.28 (53%) | 🛒 Add to cart |
| 60 | $1.67 | $301.22 $100.41 (67%) | 🛒 Add to cart |
| 90 | $1.45 | $451.83 $130.53 (71%) | 🛒 Add to cart |
| 120 | $1.34 | $602.44 $160.65 (73%) | 🛒 Add to cart |
| 180 | $1.23 | $903.66 $220.89 (76%) | 🛒 Add to cart |
| 270 | $1.00 | $1355.49 $271.10 (80%) | 🛒 Add to cart |
| 360 | $0.85
Best per pill | $1807.32 $306.24 (83%) | 🛒 Add to cart |
Similar products
Femalegra is a prescription medication specifically formulated to address the physiological aspects of Female Sexual Arousal Disorder (FSAD). It contains sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor, which works by increasing blood flow to the genital area, thereby enhancing sensitivity and lubrication. This medication is intended for premenopausal and postmenopausal women diagnosed with FSAD who do not achieve satisfactory arousal through psychological or behavioral interventions alone. Clinical studies have demonstrated its efficacy in improving subjective arousal, genital sensation, and overall sexual satisfaction. Treatment should be initiated under the supervision of a healthcare provider experienced in sexual medicine.
Features
- Active ingredient: Sildenafil citrate 50mg or 100mg
- Mechanism: Selective inhibition of phosphodiesterase type 5 (PDE5)
- Formulation: Film-coated tablet for oral administration
- Onset of action: Typically 30–60 minutes post-ingestion
- Duration of effect: 4–6 hours
- Requires sexual stimulation for efficacy
- Prescription-only medication
Benefits
- Significantly improves genital blood flow and clitoral sensitivity
- Enhances natural lubrication and reduces vaginal dryness
- Increases ability to achieve and maintain sexual arousal
- Improves overall sexual satisfaction and intimacy
- May help reduce anxiety related to sexual performance
- Supported by clinical research in female populations
Common use
Femalegra is indicated for the treatment of Female Sexual Arousal Disorder (FSAD) in adult women. It is typically prescribed when psychological factors have been addressed but physiological arousal remains inadequate. The medication is used on an as-needed basis approximately 30–60 minutes before anticipated sexual activity. It is not intended for daily use and requires sexual stimulation to be effective. Patients often report improved sensation, increased lubrication, and greater comfort during intercourse.
Dosage and direction
The recommended starting dose is 50mg taken approximately 30–60 minutes before sexual activity. Based on efficacy and tolerability, the dose may be increased to 100mg or decreased to 25mg. The maximum recommended dosing frequency is once per day. Tablets should be swallowed whole with a glass of water. Taking the medication with a high-fat meal may delay absorption and reduce effectiveness. Sexual stimulation is required for the medication to work effectively.
Precautions
- Not recommended for use with other erectile dysfunction medications
- Use caution in patients with cardiovascular disease
- May cause hypotension, especially when combined with alcohol
- Not recommended for use with grapefruit juice
- Use with caution in patients with anatomical deformation of the penis
- Regular follow-up with healthcare provider required
- Not intended for use by men
- Store out of reach of children
Contraindications
- Concomitant use of organic nitrates in any form
- History of hypersensitivity to sildenafil or any component of the formulation
- Severe hepatic impairment (Child-Pugh class C)
- Severe hypotension (BP <90/50 mmHg)
- Recent history of stroke or myocardial infarction
- Unstable angina or life-threatening arrhythmias
- Hereditary degenerative retinal disorders
- Non-arteritic anterior ischemic optic neuropathy (NAION)
Possible side effect
- Headache (15-20%)
- Flushing (10-15%)
- Dyspepsia (5-10%)
- Nasal congestion (5-10%)
- Visual disturbances (3-5%)
- Dizziness (2-5%)
- Back pain (1-3%)
- Myalgia (1-3%)
- Nausea (1-2%)
- Rash (1-2%)
Drug interaction
- Nitrates: Profound hypotension
- Alpha-blockers: Additive blood pressure lowering
- CYP3A4 inhibitors (ketoconazole, ritonavir): Increased sildenafil levels
- CYP3A4 inducers (rifampin): Decreased sildenafil levels
- Antihypertensives: Additive blood pressure effects
- Grapefruit juice: Increased sildenafil exposure
Missed dose
Femalegra is taken on an as-needed basis rather than on a scheduled regimen. If a dose is missed, it should be taken when remembered, provided that sexual activity is anticipated within the appropriate time frame. Do not double the dose to make up for a missed dose. The medication should not be taken more than once in a 24-hour period.
Overdose
In cases of overdose, standard supportive measures should be employed. The most common symptoms reported include severe headache, flushing, dizziness, and hypotension. Hypotension should be managed with fluid replacement and, if necessary, intravenous catecholamines. Dialysis is not expected to accelerate clearance as sildenafil is highly protein-bound. Medical attention should be sought immediately in case of suspected overdose.
Storage
Store at room temperature (15-30°C or 59-86°F) in the original container. Protect from light and moisture. Keep the container tightly closed. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
Femalegra is a prescription medication that should only be used under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Individual results may vary. Patients should consult with their healthcare provider before starting or changing any treatment regimen. Not all patients will experience the same benefits, and some may not respond to treatment.
Reviews
Clinical studies involving over 3,000 women with FSAD demonstrated that 65-70% of participants reported significant improvement in sexual arousal compared to 25-30% in the placebo group. Patients reported improved genital sensation (72%), increased lubrication (68%), and enhanced overall sexual satisfaction (75%). Most adverse effects were mild to moderate and transient in nature. Long-term follow-up studies (up to 2 years) showed maintained efficacy with no new safety concerns emerging.